Refine
Has Fulltext
- yes (22)
Is part of the Bibliography
- yes (22) (remove)
Year of publication
Document Type
- Journal article (15)
- Doctoral Thesis (7)
Keywords
- chemotherapy (22) (remove)
Institute
- Theodor-Boveri-Institut für Biowissenschaften (5)
- Institut für diagnostische und interventionelle Neuroradiologie (ehem. Abteilung für Neuroradiologie) (3)
- Klinik und Poliklinik für Allgemein-, Viszeral-, Gefäß- und Kinderchirurgie (Chirurgische Klinik I) (3)
- Medizinische Klinik und Poliklinik II (3)
- Institut für Hygiene und Mikrobiologie (2)
- Medizinische Klinik und Poliklinik I (2)
- Frauenklinik und Poliklinik (1)
- Graduate School of Life Sciences (1)
- Institut für Pharmazie und Lebensmittelchemie (1)
- Institut für Psychotherapie und Medizinische Psychologie (1)
Background: Combination of oncolytic vaccinia virus therapy with conventional chemotherapy has shown promise for tumor therapy. However, side effects of chemotherapy including thrombocytopenia, still remain problematic. Methods: Here, we describe a novel approach to optimize combination therapy of oncolytic virus and chemotherapy utilizing virus-encoding hyper-IL-6, GLV-1h90, to reduce chemotherapy-associated side effects. Results: We showed that the hyper-IL-6 cytokine was successfully produced by GLV-1h90 and was functional both in cell culture as well as in tumor-bearing animals, in which the cytokine-producing vaccinia virus strain was well tolerated. When combined with the chemotherapeutic mitomycin C, the anti-tumor effect of the oncolytic virotherapy was significantly enhanced. Moreover, hyper-IL-6 expression greatly reduced the time interval during which the mice suffered from chemotherapy-induced thrombocytopenia. Conclusion: Therefore, future clinical application would benefit from careful investigation of additional cytokine treatment to reduce chemotherapy-induced side effects.